<DOC>
	<DOCNO>NCT02624908</DOCNO>
	<brief_summary>24-week , randomize , double blind , placebo-controlled trial evaluate safety efficacy canagliflozin compare placebo reduce need mealtime insulin subject type 2 diabetes currently use basal-bolus insulin regimen .</brief_summary>
	<brief_title>Canagliflozin-Mealtime Insulin Rescue</brief_title>
	<detailed_description>The Canagliflozin Mealtime Insulin Rescue study enroll 40 subject Atlanta VA Medical Center . Subjects screen enter 2-week run-in period switch continue diabetes treatment regimen basal insulin supper aspart insulin meal . Run-in useful evaluate compliance treatment self-monitoring . After run-in , subject collect one week baseline glycemic data regular pre-meal fasting glycemic level use finger stick test continuous glucose monitoring . Subjects randomize Visit 3 100 mg canagliflozin placebo . If well tolerate , dose increase 300 mg canagliflozin placebo Visit 4 . Diabetes management assure regular contact study team ( weekly call clinic visit Weeks 4 , 8 , 16 24 ) . Management facilitate diabetes management software . Self-monitoring continuous glucose monitoring repeat end study participation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>use basalbolus insulin onset diabetes age 30 BMI less 35 eGFR least 60 ml/mn Hb A1c 7.59.0 % total daily insulin dosage le 100 unit willingness perform home glucose monitor willingness transmit glucose medication information weekly Type 1 diabetes Known coronary cerebrovascular disease peripheral artery disease Liver enzymes equal 1.5 time upper limit normal Chronic heart failure NYHA class III IV Current haemodialysis peritoneal dialysis End stage liver disease , define acute chronic liver disease recent history one following : ascites , encephalopathy , variceal bleeding , bilirubin equal great 2.0 mg/dL , albumin equal less 3.5 g/ dL , prothrombin time great equal 4 second , INR great equal 1.7 prior liver transplant Known suspect hypersensitivity trial product relate product Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method require law local practice . Expected simultaneous participation clinical trial investigational medicinal product . Receipt investigational medicinal product within 30 day randomization Current past ( within last 5 year ) malignant neoplasm ( except basal cell squamous cell skin carcinoma ) Any condition investigator 's opinion would make subject unable adhere trial visit schedule procedure Known history noncompliance treatment .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>